{"id":"c8e4c3a4-3adf-54fa-a2f3-8dc4656b10c8","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-ck2-alpha-prime-holo","predicate":"decreases_in_recorded_comparison","statement":"Apigenin inhibited this human CK2 preparation with IC50 2.5 micromolar using P2B substrate and 2.4 micromolar using the peptide substrate.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"64cfe011-80dc-5d78-bb3c-d200cc61dbe4","mechanism_event_label":"Apigenin inhibited this human CK2 preparation with IC50 2.5 micromolar using P2B substrate and 2.4 micromolar using the peptide substrate.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"8c3eb79c-4a30-5a53-a409-e1c4a4cea639","slug":"human-ck2-alpha-prime-holoenzyme","display_name":"Human CK2 alpha-prime/beta reconstituted holoenzyme","entity_type_key":"protein_complex"},"evidence_count":1,"mechanism_event":{"id":"64cfe011-80dc-5d78-bb3c-d200cc61dbe4","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-ck2-alpha-prime-holo-event","event_type":"biochemical_relationship","label":"Apigenin inhibited this human CK2 preparation with IC50 2.5 micromolar using P2B substrate and 2.4 micromolar using the peptide substrate.","description":"### api-ck2-alpha-prime-holo\n\nApigenin inhibited this human CK2 preparation with IC50 2.5 micromolar using P2B substrate and 2.4 micromolar using the peptide substrate.\nSubunit identity and assay substrate are part of the potency result; no universal IC50 or physiological ATP correction is implied.\nModel and exposure: Recombinant human CK2; ATP 20 micromolar; Table 1.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Inhibitory influence of natural flavonoids on human protein kinase CK2 isoforms: effect of the regulatory subunit. | 2018 | https://pubmed.ncbi.nlm.nih.gov/29188536/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6002439/ | https://doi.org/10.1007/s11010-017-3228-1 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin concentration series","sequence_order":0,"notes":""},{"entity":{"id":"8c3eb79c-4a30-5a53-a409-e1c4a4cea639","slug":"human-ck2-alpha-prime-holoenzyme","display_name":"Human CK2 alpha-prime/beta reconstituted holoenzyme","entity_type_key":"protein_complex"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"58b974f1-d389-5bf6-81cd-889c44442c42","slug":"atp","display_name":"ATP","entity_type_key":"small_molecule"},"role":"assay phosphoryl donor","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin concentration series\", \"comparator\": \"No inhibitor\", \"endpoint\": \"Apigenin inhibited this human CK2 preparation with IC50 2.5 micromolar using P2B substrate and 2.4 micromolar using the peptide substrate.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Recombinant human CK2; ATP 20 micromolar; Table 1.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin inhibited this human CK2 preparation with IC50 2.5 micromolar using P2B substrate and 2.4 micromolar using the peptide substrate.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Inhibitory influence of natural flavonoids on human protein kinase CK2 isoforms: effect of the regulatory subunit. | https://pubmed.ncbi.nlm.nih.gov/29188536/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6002439/ | https://doi.org/10.1007/s11010-017-3228-1","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-ck2-alpha-prime-holo; Subunit identity and assay substrate are part of the potency result; no universal IC50 or physiological ATP correction is implied.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"14165f90-3571-5770-ab5f-2073669fd524","evidence_kind":"source_excerpt","locator":"Lines 624-630","start_line":624,"end_line":630,"excerpt":"### api-ck2-alpha-prime-holo\n\nApigenin inhibited this human CK2 preparation with IC50 2.5 micromolar using P2B substrate and 2.4 micromolar using the peptide substrate.\nSubunit identity and assay substrate are part of the potency result; no universal IC50 or physiological ATP correction is implied.\nModel and exposure: Recombinant human CK2; ATP 20 micromolar; Table 1.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Inhibitory influence of natural flavonoids on human protein kinase CK2 isoforms: effect of the regulatory subunit. | 2018 | https://pubmed.ncbi.nlm.nih.gov/29188536/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6002439/ | https://doi.org/10.1007/s11010-017-3228-1 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Recombinant human CK2; ATP 20 micromolar; Table 1.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}